KPC Cell Line (C57/BL6 genetic background)
Syngeneic pancreatic ductal adenocarcinoma (PDA) cell line from the KPC mouse model for immune-competent studies in drug discovery, biomarker development, genetic research, and metastasis
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
The KPC C57BL/6 cell line is derived from spontaneous pancreatic tumours of the Kras^G12D/+; Trp53^R172H/+; Pdx1-Cre genetically engineered KPC mouse model and backcrossed onto the immunocompetent C57BL/6 background. It retains both driver mutations — KRAS^G12D and TP53^R172H — which are among the most common genetic alterations in human pancreatic ductal adenocarcinoma (PDA).
When implanted orthotopically or subcutaneously into immunocompetent C57BL/6 mice, this line produces robust, reproducible tumours reminiscent of human pancreatic cancer.
Key features
- Endogenous KRAS^G12D and TP53^R172H mutations reflecting human PDA genetics
- Fully congenic on the C57BL/6 background following ten generations of backcrossing
- Reliable orthotopic and subcutaneous tumour formation in immunocompetent hosts
Applications
- Preclinical drug discovery
- Biomarker identification and validation
- Genetic research
- Metastasis modelling
- Immuno-oncology research, including evaluation of KRAS dependency and tumour–immune interactions
